Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators

• US 20050054725A1
• Filed: 08/18/2004
• Published: 03/10/2005
• Est. Priority Date: 12/20/2002
• Status: Abandoned Application

• Current Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Original Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Inventors: Thor, Karl Bruce, Fraser, Matthew Oliver, Burgard, Edward C.
• Application Number:
  US10/920,483
• Publication Number:
  US 20050054725A1
• Time in Patent Office: Days
• US Class Current: 514/561
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α₂δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the α₂δ calcium channel subunit.

Claims

1. A method for treating nocturia comprising administering a therapeutically effective amount of an α

₂δ

subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin.

2. A method for treating urinary frequency comprising administering a therapeutically effective amount of an α

₂δ

subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin.

3. A method for treating urinary urgency comprising administering a therapeutically effective amount of an α

₂δ

subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin.